The Manila Times

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2ZORYVE cream 0.05% provides rapid clearance of atopic dermatitisZORYVE can ...

Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical ...

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.
Mena FN

FDA Approves Arcutis' ZORYVE® (Roflumilast) Cream 0.05% For The Treatment Of Atopic Dermatitis In Children Ages 2 To 5

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere ...
The Malaysian Reserve

Lilly’s EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis

New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half the ...

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to ...

Tori Spelling shares her and her family’s journey with eczema and seborrheic dermatitis to encourage others to take control of their skin ...

Castle Biosciences, Inc. (CSTL) Q3 2025 Earnings Call Transcript

Q3 2025 Earnings Call November 3, 2025 4:30 PM ESTCompany ParticipantsCamilla Zuckero - Vice President of Investor ...
Healio

Q&A: Navigating the ‘noise’ to advocate for people with eczema

More than 31 million people in the U.S. live with eczema, a chronic skin condition that can disrupt daily life yet continues ...